Trials / Not Yet Recruiting

Not Yet RecruitingNCT07355764

MA-CRC-II-016 SHR-1811

SHR-1811 Combined With Bevacizumab as Second-line Treatment in Patients Metastatic CRC

Status: Not Yet Recruiting
Phase: Phase 2
Study type: Interventional
Enrollment: 80 (estimated)

Sponsor: Peking Union Medical College Hospital · Academic / Other
Sex: All
Age: 18 Years – 75 Years
Healthy volunteers: Not accepted

Summary

A randomized, controlled, multicenter clinical study of SHR-A1811 combined with bevacizumab for the second-line treatment of metastatic colorectal cancer

Conditions

mCRC
HER2
Targeted Therapy
Antibody-drug Conjugates

Interventions

Type	Name	Description
DRUG	SHR-A1811 & Bevacizumab injection	HER2 ADC
DRUG	Chemotherapeutic Combinations	FOLFIRI+BEV

Timeline

Start date: 2025-12-30
Primary completion: 2028-01-30
Completion: 2028-01-31
First posted: 2026-01-21
Last updated: 2026-01-21

Source: ClinicalTrials.gov record NCT07355764. Inclusion in this directory is not an endorsement.